• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

多发性骨髓瘤患者在自体干细胞移植期间感染新型冠状病毒肺炎：病例报告及文献综述

The patients with multiple myeloma were infected with COVID-19 during autologous stem cell transplantation: case report and literature review.

作者信息

Su Chang, Huang Lijun, Liang Liang, Ou Lijia, Lu Guige, Wang Caiqin, He Yizi, Zeng Ruolan, Li Yajun, Zhou Hui, Xiao Ling

机构信息

Department of Lymphoma & Hematology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, No. 283 Tongzipo Road, Yuelu District, Changsha, Hunan, China.

Department of Histology and Embryology, Xiangya School of Medicine, Central South University, No. 172 Tongzipo Road, Yuelu District, Changsha, Hunan, China.

出版信息

Infect Agent Cancer. 2024 May 27;19(1):25. doi: 10.1186/s13027-024-00587-2.

DOI:10.1186/s13027-024-00587-2
PMID:38802946
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11131194/
Abstract

This paper introduces two cases of multiple myeloma, COVID-19 infection during autologous stem cell transplantation, the treatment process, and different results of the two patients, which provides a reference for how to carry out ASCT safely during the COVID-19 normalization stage.

摘要

本文介绍了两例多发性骨髓瘤患者在自体干细胞移植期间感染新型冠状病毒肺炎（COVID-19）的病例、治疗过程以及两名患者的不同结果，为在COVID-19常态化阶段如何安全进行自体干细胞移植（ASCT）提供了参考。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be37/11131194/c2be4fe40997/13027_2024_587_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be37/11131194/e68d50a31c3b/13027_2024_587_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be37/11131194/c2be4fe40997/13027_2024_587_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be37/11131194/e68d50a31c3b/13027_2024_587_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be37/11131194/c2be4fe40997/13027_2024_587_Fig2_HTML.jpg

相似文献

1
The patients with multiple myeloma were infected with COVID-19 during autologous stem cell transplantation: case report and literature review.多发性骨髓瘤患者在自体干细胞移植期间感染新型冠状病毒肺炎：病例报告及文献综述
Infect Agent Cancer. 2024 May 27;19(1):25. doi: 10.1186/s13027-024-00587-2.
2
The impact of COVID-19 on autologous stem cell transplantation in multiple myeloma: A single-centre, qualitative evaluation study.COVID-19 对多发性骨髓瘤自体干细胞移植的影响：一项单中心定性评估研究。
Support Care Cancer. 2022 Sep;30(9):7469-7479. doi: 10.1007/s00520-022-07173-5. Epub 2022 Jun 3.
3
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.高剂量化疗联合自体造血干细胞移植作为既往自体造血干细胞移植后复发多发性骨髓瘤患者的巩固治疗（NCRI 骨髓瘤 X 复发[强化试验]）：一项随机、开放标签、3 期试验。
Lancet Oncol. 2014 Jul;15(8):874-85. doi: 10.1016/S1470-2045(14)70245-1. Epub 2014 Jun 16.
4
Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.硼替佐米联合地塞米松序贯治疗多发性骨髓瘤患者随后进行自体造血干细胞移植。
Chin Med J (Engl). 2012 Dec;125(24):4454-9.
5
Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study.肾功能损害对多发性骨髓瘤自体干细胞移植后结局的影响：一项多中心、回顾性队列研究。
BMC Cancer. 2018 Oct 20;18(1):1008. doi: 10.1186/s12885-018-4926-0.
6
Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma.与单独使用达雷妥尤单抗、泊马度胺和地塞米松（DPd）相比，对于复发难治性多发性骨髓瘤患者，采用达雷妥尤单抗、泊马度胺和地塞米松（DPd）方案后进行高剂量化疗-自体干细胞移植可带来更好的疗效。
Transplant Cell Ther. 2023 Apr;29(4):262.e1-262.e6. doi: 10.1016/j.jtct.2023.01.013. Epub 2023 Jan 20.
7
Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment.诱导治疗后达到微小残留病灶不可检测的多发性骨髓瘤患者自体干细胞移植的临床获益。
Cancer Res Commun. 2023 Sep 6;3(9):1770-1780. doi: 10.1158/2767-9764.CRC-23-0185. eCollection 2023 Sep.
8
Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial.基于硼替佐米的再诱导治疗后自体移植后复发骨髓瘤的干细胞采集：英国血液与骨髓移植学会/英国骨髓瘤论坛骨髓瘤X（强化）试验结果
Biol Blood Marrow Transplant. 2016 Jun;22(6):1009-1016. doi: 10.1016/j.bbmt.2016.01.016. Epub 2016 Jan 28.
9
Prognostic impact of natural killer cell recovery on minimal residual disease after autologous stem cell transplantation in multiple myeloma.自然杀伤细胞恢复对多发性骨髓瘤自体干细胞移植后微小残留病的预后影响。
Transpl Immunol. 2022 Apr;71:101544. doi: 10.1016/j.trim.2022.101544. Epub 2022 Jan 31.
10
Risk Factors for Catheter-Related Thrombosis in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.多发性骨髓瘤患者自体造血干细胞移植后与导管相关血栓形成的危险因素。
Medicina (Kaunas). 2021 Sep 26;57(10):1020. doi: 10.3390/medicina57101020.

引用本文的文献

1
Patients with multiple myeloma infected with COVID-19 during autologous stem cell transplantation.在自体干细胞移植期间感染新冠病毒的多发性骨髓瘤患者。
Infect Agent Cancer. 2024 Aug 12;19(1):38. doi: 10.1186/s13027-024-00603-5.

本文引用的文献

1
Risk factors of early disease progression and decreased survival for multiple myeloma patients after upfront autologous stem cell transplantation.初诊自体干细胞移植后多发性骨髓瘤患者早期疾病进展和生存降低的风险因素。
Ann Hematol. 2024 Aug;103(8):2893-2904. doi: 10.1007/s00277-024-05641-y. Epub 2024 Mar 13.
2
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN).《后疫情时代多发性骨髓瘤合并 COVID-19 患者的管理：来自欧洲骨髓瘤网络（EMN）的共识文件》。
Leukemia. 2023 Jun;37(6):1175-1185. doi: 10.1038/s41375-023-01920-1. Epub 2023 May 4.
3
Radiotherapy in COVID-19 patient affected by multiple myeloma: a case report.
新型冠状病毒肺炎合并多发性骨髓瘤患者的放射治疗：一例报告
Transl Cancer Res. 2020 Dec;9(12):7662-7668. doi: 10.21037/tcr-20-2172.
4
Diagnosis and Management of Multiple Myeloma: A Review.多发性骨髓瘤的诊断与治疗：综述
JAMA. 2022 Feb 1;327(5):464-477. doi: 10.1001/jama.2022.0003.
5
Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls.多发性骨髓瘤患者对 COVID-19 mRNA 疫苗的反应与对照组相比是保守的，但受到了损害。
J Hematol Oncol. 2021 Oct 13;14(1):166. doi: 10.1186/s13045-021-01183-2.
6
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose.骨髓瘤老年患者在接种第一剂BNT162b2疫苗后对新冠病毒的中和抗体反应较低。
Blood. 2021 Jul 1;137(26):3674-3676. doi: 10.1182/blood.2021011904.
7
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study.造血干细胞移植受者 COVID-19 的临床特征和结局：一项观察性队列研究。
Lancet Haematol. 2021 Mar;8(3):e185-e193. doi: 10.1016/S2352-3026(20)30429-4. Epub 2021 Jan 19.
8
Cancer Statistics, 2021.癌症统计数据，2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
9
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set.与 COVID-19 多发性骨髓瘤患者结局相关的临床特征：国际骨髓瘤学会数据集的初步结果。
Blood. 2020 Dec 24;136(26):3033-3040. doi: 10.1182/blood.2020008150.
10
Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison.前线达妥木单抗-VTd 与适合 ASCT 的多发性骨髓瘤的标准治疗的比较：匹配调整后的间接比较。
Immunotherapy. 2021 Feb;13(2):143-154. doi: 10.2217/imt-2020-0266. Epub 2020 Nov 24.